Friday, 20 Jul 2018

You are here

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

  1. Study of 16207 RA patients >65yrs shows non-serious infection rate of 47.5/100PY; increased 20% by steroid use.Infx common in RA
  2. Rules for Drug Cessation with Infection 
  3. 241 patients with Clinically suspect arthralgia - Positive Serology increases RA risk: CCP HR 8.5; RF 5.1; CarbP Ab 3.9; RF+CCP+ has PPV 67%
  4. Frequence of Secondary Sjogrens is 20% in RA and 14% in SLE - with a >15 to 1 female to male ratio
  5. Lower RA dz activity & remission assoc w/ lower serious infection rates! Inflammation (not drugs) drives infx risk
  6. 107 JIA pts followed for 3 yrs on Biologics- 25% (35) had Serious/Opportunistic infx. range 10.6-14.8/100py
  7. In 19 RCTs, 6194 RA pts received tofacitinib for 19406 pt-Yrs & 19 developed lymphoma (SIR 2.62) or 1:1000 PY risk
  8. 2016 US Top selling drugs: Humira $13.6 billion, Enbrel $7.4 billion, Remicade $5.3 billion, Lyrica $4.4B,RTX $3.9B
  9. Idiopathic arthralgias pts with no US synovitis have negative predictive value 89% for developing inflam arthritis
  10. RA RCT Inclusion of FM or Depression pts or pts on SSRI had 10% less ACR20 & 1/2 LDAS responses, more W/D & AE
  11. In 7-15% PSA precedes Pso;In remainder, median time from PSO dx to PsA is 7-8yrs. <75% get PsA w/in 10-15 yrs of PsO
  12. IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
  13. Patterns of Biologic Use During Autoimmune Pregnancy 
  14. Alcohol Related Deaths Increased in Psoriasis



The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – Cocoon Therapy? (7.20.18)

Dr. Jack Cush reviews highlights from the news and social media on in the past week. 

Proposed Changes for 2019 Medicare Fee Schedule

On July 12th the Centers for Medicare & Medicaid Services (CMS) released its proposed rule changes for the 2019 Medicare physician fee schedule.  This year, CMS has combined the Medicare physician fee schedule proposed rule with recommendations for the Quality Payment Program (QPP), which will be officially published in the Federal Register on July 27.

Trend Towards Fewer Self-Employed Physicians


A nationwide survey study analyzed healthcare provider (HCP) employment type (self-employed, employed by private sector, or employed by government) and annual labor earnings (2001 to 2015) and found that the health care landscape is changing with few self-employed practitioners and more being larger organizations. 

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on